Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.64 USD
+0.07 (4.46%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $1.63 -0.01 (-0.61%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Coherus BioSciences (CHRS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.17 | $12.00 | $4.00 | 398.17% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Coherus BioSciences comes to $8.17. The forecasts range from a low of $4.00 to a high of $12.00. The average price target represents an increase of 398.17% from the last closing price of $1.64.
Analyst Price Targets (6 )
Broker Rating
Coherus BioSciences currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy, representing 70% of all recommendations. A month ago, Strong Buy represented 70%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CHRS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
5/18/2024 | Maxim Group | Michael Okunewitch | Hold | Hold |
5/13/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Michael Nedelcovych | Strong Buy | Strong Buy |
3/14/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
2/8/2024 | UBS | Ashwani Verma | Strong Buy | Strong Buy |
1/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/30/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.60 |
# of Recs in ABR | 10 |
Average Target Price | $8.17 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.21 |